Trial Profile
A Phase 1, Open-Label Study to Determine the Effect of Calories and Fat Content on the Pharmacokinetics of Repeated Dose Lurasidone 120 mg in Subjects With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Dainippon Sumitomo Pharma; Sunovion Pharmaceuticals
- 02 Mar 2010 New trial record